MedWatch

No room for more mistakes at Lundbeck

Pharmaceutical company Lundbeck has a lot of work to do if it is to live up to its own long-term ambitions, analysts say. The company believes it can be done.

Lundbeck HQ in Valby, Copenhagen | Photo: Lundbeck / PR

Lundbeck is treading water to avoid being overcome by falling share prices, high costs, low growth and a lack of earnings compared to others in the industry. Despite this, company leaders are optimistic and believe a golden era is coming over the next 6-8 years.

That surprises Jannick Lindegaard Denholt, an analyst at ABG Sundal Collier.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs